DK3458111T3 - Immunomodulatorer til pet-billeddannelse - Google Patents

Immunomodulatorer til pet-billeddannelse Download PDF

Info

Publication number
DK3458111T3
DK3458111T3 DK17728696.0T DK17728696T DK3458111T3 DK 3458111 T3 DK3458111 T3 DK 3458111T3 DK 17728696 T DK17728696 T DK 17728696T DK 3458111 T3 DK3458111 T3 DK 3458111T3
Authority
DK
Denmark
Prior art keywords
immunom
modulators
image formation
pet image
pet
Prior art date
Application number
DK17728696.0T
Other languages
Danish (da)
English (en)
Inventor
David J Donnelly
Kenneth M Boy
Joonyoung Kim
Adrienne Pena
Yunhui Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3458111T3 publication Critical patent/DK3458111T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12Arrangements for detecting or locating foreign bodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17728696.0T 2016-05-19 2017-05-17 Immunomodulatorer til pet-billeddannelse DK3458111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
DK3458111T3 true DK3458111T3 (da) 2021-04-26

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17728696.0T DK3458111T3 (da) 2016-05-19 2017-05-17 Immunomodulatorer til pet-billeddannelse

Country Status (25)

Country Link
US (2) US11103605B2 (cg-RX-API-DMAC7.html)
EP (2) EP3827849A1 (cg-RX-API-DMAC7.html)
JP (1) JP6953444B2 (cg-RX-API-DMAC7.html)
KR (1) KR102378288B1 (cg-RX-API-DMAC7.html)
CN (1) CN109414514B (cg-RX-API-DMAC7.html)
AU (1) AU2017268291B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018073642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024844A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124241T1 (cg-RX-API-DMAC7.html)
DK (1) DK3458111T3 (cg-RX-API-DMAC7.html)
EA (1) EA038019B1 (cg-RX-API-DMAC7.html)
ES (1) ES2864091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210644T8 (cg-RX-API-DMAC7.html)
HU (1) HUE054306T2 (cg-RX-API-DMAC7.html)
IL (1) IL262962B (cg-RX-API-DMAC7.html)
LT (1) LT3458111T (cg-RX-API-DMAC7.html)
MA (1) MA53402A (cg-RX-API-DMAC7.html)
MX (1) MX2018014028A (cg-RX-API-DMAC7.html)
PL (1) PL3458111T3 (cg-RX-API-DMAC7.html)
PT (1) PT3458111T (cg-RX-API-DMAC7.html)
RS (1) RS61742B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810177VA (cg-RX-API-DMAC7.html)
SI (1) SI3458111T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100238T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017201111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
EP3558395A4 (en) 2016-12-23 2020-08-12 The Johns Hopkins University IMAGING OF TUMOR CELLS AND IMMUNE CELLS BASED ON PD-L1 EXPRESSION
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
EP4121442A1 (en) * 2020-03-16 2023-01-25 Bristol-Myers Squibb Company Immunomodulators
WO2021202501A1 (en) 2020-03-30 2021-10-07 Bristol-Myers Squibb Company Immunomodulators
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
EP4634205A2 (en) * 2022-12-12 2025-10-22 Merck Sharp & Dohme LLC Cyclic peptides as pet imaging agents of granzyme b

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
ATE380038T1 (de) 1996-07-12 2007-12-15 Immunomedics Inc Radiometall-bindende peptide analoge
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
CA2302360C (en) 1997-09-03 2005-11-15 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US10195578B2 (en) 2010-12-03 2019-02-05 The University Of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
MX2014011353A (es) 2012-03-29 2014-12-05 Aurigene Discovery Tech Ltd Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
MY176706A (en) 2013-03-15 2020-08-19 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
HUE039012T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EA037590B1 (ru) * 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
CA2968961A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
PT3458111T (pt) 2021-04-09
KR20190009330A (ko) 2019-01-28
EP3458111B1 (en) 2021-03-03
AU2017268291B2 (en) 2022-09-29
SG11201810177VA (en) 2018-12-28
IL262962A (en) 2018-12-31
EA201892635A1 (ru) 2019-04-30
JP6953444B2 (ja) 2021-10-27
WO2017201111A1 (en) 2017-11-23
AU2017268291A1 (en) 2019-01-17
RS61742B1 (sr) 2021-05-31
SI3458111T1 (sl) 2021-07-30
EP3458111A1 (en) 2019-03-27
EA038019B1 (ru) 2021-06-23
HRP20210644T1 (hr) 2021-05-28
MX2018014028A (es) 2019-04-04
CY1124241T1 (el) 2022-07-22
BR112018073642A2 (pt) 2019-02-26
SMT202100238T1 (it) 2021-05-07
CN109414514B (zh) 2022-03-11
CA3024844A1 (en) 2017-11-23
HUE054306T2 (hu) 2021-08-30
JP2019520328A (ja) 2019-07-18
HRP20210644T8 (hr) 2021-06-25
US20190117801A1 (en) 2019-04-25
MA53402A (fr) 2021-06-02
PL3458111T3 (pl) 2021-06-28
ES2864091T3 (es) 2021-10-13
US11103605B2 (en) 2021-08-31
KR102378288B1 (ko) 2022-03-23
IL262962B (en) 2020-04-30
EP3827849A1 (en) 2021-06-02
LT3458111T (lt) 2021-05-25
US20210386876A1 (en) 2021-12-16
CN109414514A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
DK3458111T3 (da) Immunomodulatorer til pet-billeddannelse
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
MA55328A (fr) Modulateurs de ror-gamma
MA53943A (fr) Modulateurs de ror-gamma
EP3442971C0 (en) ESTROGEN RECEPTOR MODULATORS
EP3476272A4 (en) IMAGE
EP3116401C0 (en) Anatomical image projection system
EP3532062A4 (en) ROR GAMMA MODULATORS
EP3477362A4 (en) ELECTROOPTICAL MODULATOR
HUE053189T2 (hu) Rendszer javított képek elõállítására
FR3028076B1 (fr) Architecture logicielle pour systeme expert
EP3555693A4 (en) Imaging system
DK3468620T3 (da) 18f-mærkede bisphosphonater til pet-billeddannelse
DK3484528T3 (da) Tau-pet-billeddannelsesligander
UA34137S (uk) Зображення для етикетки
DE112017003617A5 (de) Farbwechselsystem
DK3428116T3 (da) Longeringsgjord til heste
UA33870S (uk) Графічне зображення
UA33869S (uk) Графічне зображення
UA33868S (uk) Графічне зображення
UA33693S (uk) Графічне зображення
UA33616S (uk) Графічне зображення
UA32104S (uk) Зображення для етикетки
UA32103S (uk) Зображення для етикетки